1 January 2011PatentsArchana Shanker

A revolution: biotech patents in India

In May 2011, Glenmark Pharmaceuticals entered into a licence agreement with Sanofi Aventis in one of the first-ever deals for a novel biologic molecule in India for the treatment of autoimmune diseases. Bharat Biotech, an Indian Biotech company, developed a diarrhoea vaccine to be supplied to the UN and other markets at $1 each, making it the cheapest vaccine available in the market.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Jurisdiction reports

India jurisdiction report: Defending domain names

14 August 2020 With the rapid growth of the internet and globalisation, the marketing of products and services through websites and domain names has become a vital part of brand-building and commerce for trademark owners.

India: Patents-in-waiting

23 September 2019 With pendency rates ranging up to four years, India’s patent owners have a range of options to protect their innovations while they wait, explains Joginder Singh of LexOrbis.

UK-India trade deal is ‘missed opportunity’, say industry bodies

WATCH: Recent developments in design patent law

SEPs now searchable on WIPO’s global patent database

'Nothing can stand in the way of our work': Ukraine resumes IP system

WATCH: Finding a new balance in IP protection with trade secret protection

Optis v Apple: How the court calculated the royalty rate

Apple must pay Optis $700m-the biggest patent award in UK history

Wouter Pors leaves Bird & Bird for boutique Dutch firm

A revolution: biotech patents in India

More on this story

Editor's picks

Editor's picks

More articles